212 related articles for article (PubMed ID: 19536511)
1. [Neutrophil-rich, anaplastic CD30+ T cell lymphoma in conjunction with lymphomatoid papulosis].
Slotosch CM; Hörster S; Hertl M; Schultz E
Hautarzt; 2010 Jun; 61(6):511-3. PubMed ID: 19536511
[TBL] [Abstract][Full Text] [Related]
2. CD30-positive atypical lymphoid cells in common non-neoplastic cutaneous infiltrates rich in neutrophils and eosinophils.
Cepeda LT; Pieretti M; Chapman SF; Horenstein MG
Am J Surg Pathol; 2003 Jul; 27(7):912-8. PubMed ID: 12826883
[TBL] [Abstract][Full Text] [Related]
3. Lymphomatoid Papulosis and Other Lymphoma-Like Diseases.
Moy A; Sun J; Ma S; Seminario-Vidal L
Dermatol Clin; 2019 Oct; 37(4):471-482. PubMed ID: 31466587
[TBL] [Abstract][Full Text] [Related]
4. A case of lymphomatoid papulosis type E in a young adult: An uncommon entity.
Rajashekara Swamy M; Pollock S; J Goldberg L; Shen L
J Cutan Pathol; 2021 May; 48(5):694-700. PubMed ID: 33533041
[TBL] [Abstract][Full Text] [Related]
5. Type A lymphomatoid papulosis presenting as an eyelid ulcer in a young man.
Sánchez España JC; Secondi R
Orbit; 2019 Dec; 38(6):495-499. PubMed ID: 30644803
[TBL] [Abstract][Full Text] [Related]
6. Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma.
Sanka RK; Eagle RC; Wojno TH; Neufeld KR; Grossniklaus HE
Ophthalmology; 2010 Feb; 117(2):343-51. PubMed ID: 19969358
[TBL] [Abstract][Full Text] [Related]
7. [Cutaneous neutrophils infiltrates. Case 7. Lymphomatoid papulosis].
Vergier B
Ann Pathol; 2011 Jun; 31(3):198-202. PubMed ID: 21737002
[No Abstract] [Full Text] [Related]
8. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders.
Vonderheid EC; Sajjadian A; Kadin ME
J Am Acad Dermatol; 1996 Mar; 34(3):470-81. PubMed ID: 8609262
[TBL] [Abstract][Full Text] [Related]
9. Lymphomatoid papulosis in children: experience of five cases and the treatment efficacy of methotrexate.
Yip L; Darling S; Orchard D
Australas J Dermatol; 2011 Nov; 52(4):279-83. PubMed ID: 22070703
[TBL] [Abstract][Full Text] [Related]
10. Practical Management of CD30⁺ Lymphoproliferative Disorders.
Hughey LC
Dermatol Clin; 2015 Oct; 33(4):819-33. PubMed ID: 26433852
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.
Kempf W; Kerl K; Mitteldorf C
Semin Cutan Med Surg; 2018 Mar; 37(1):24-29. PubMed ID: 29719017
[TBL] [Abstract][Full Text] [Related]
12. [Primary cutaneous anaplastic large cell lymphoma with systemic progression responding to low-dose methotrexate therapy].
Sumitani R; Harada T; Nakamura M; Mizuguchi M; Oura M; Sogabe K; Maruhashi T; Takahashi M; Fujii S; Nakamura S; Miki H; Kagawa K; Yada M; Matsudate Y; Uehara H; Abe M
Rinsho Ketsueki; 2022; 63(6):536-543. PubMed ID: 35831185
[TBL] [Abstract][Full Text] [Related]
13. CD30+ lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma followed by lymphomatoid papulosis.
Aoki M; Niimi Y; Takezaki S; Azuma A; Seike M; Kawana S
Br J Dermatol; 2001 Jul; 145(1):123-6. PubMed ID: 11453920
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of a patient with lymphomatoid papulosis by methotrexate.
Yazawa N; Kondo S; Kagaya M; Yazawa H; Minamitsuji Y; Jimbow K
J Dermatol; 2001 Jul; 28(7):373-8. PubMed ID: 11510505
[TBL] [Abstract][Full Text] [Related]
15. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity.
Schwartz Z; Bowe RB; Coleman M; Magro CM
Ann Diagn Pathol; 2018 Dec; 37():57-61. PubMed ID: 30292067
[TBL] [Abstract][Full Text] [Related]
16. CD30
Sauder MB; O'Malley JT; LeBoeuf NR
Hematol Oncol Clin North Am; 2017 Apr; 31(2):317-334. PubMed ID: 28340881
[TBL] [Abstract][Full Text] [Related]
17. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies.
Wada DA; Law ME; Hsi ED; Dicaudo DJ; Ma L; Lim MS; Souza Ad; Comfere NI; Weenig RH; Macon WR; Erickson LA; Ozsan N; Ansell SM; Dogan A; Feldman AL
Mod Pathol; 2011 Apr; 24(4):596-605. PubMed ID: 21169992
[TBL] [Abstract][Full Text] [Related]
18. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Pfaltz K; Vermeer MH; Cozzio A; Ortiz-Romero PL; Bagot M; Olsen E; Kim YH; Dummer R; Pimpinelli N; Whittaker S; Hodak E; Cerroni L; Berti E; Horwitz S; Prince HM; Guitart J; Estrach T; Sanches JA; Duvic M; Ranki A; Dreno B; Ostheeren-Michaelis S; Knobler R; Wood G; Willemze R
Blood; 2011 Oct; 118(15):4024-35. PubMed ID: 21841159
[TBL] [Abstract][Full Text] [Related]
19. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
20. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
